



DDW Update 2022

CHAS MCKHANN, PRESIDENT & CEO

May 22, 2022

Forward Looking Statements & Regulatory Advisory

Forward Looking Statements: Certain statements in this presentation are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. In addition, there is uncertainty about the spread of the COVID-19 virus and the impact it may have on the Company's operations, the Company's financial outlook for future periods, the demand for the Company's products, the Company's liquidity position, global supply chains and economic activity in general. Important factors that could cause actual results to differ materially include: reports of adverse events related to our products, outcomes of clinical studies related to our products, development of competitive medical products by competitors, regulatory approvals and extensive regulatory oversight by the FDA or other regulatory authorities, unfavorable media coverage related to our products or related procedures, coverage and reimbursement decisions by private or government payors, Apollo's ability to support the adoption of its products and broaden its product portfolio; the potential size of Apollo's addressable markets; the execution of our gross margin improvement projects; and the availability of cash for Apollo's future operations as well as other factors detailed in Apollo's periodic reports filed with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2021 and Form 10-Q for the three months ended March 31, 2022. Copies of reports filed with the SEC are posted on Apollo's website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Non-GAAP Financial Measures: To supplement the Company's financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company reports certain non-GAAP financial measures, including non-GAAP operating expenses, which exclude stock-based compensation. These supplemental measures of our performance are not required by, and are not determined in accordance with GAAP. The Company believes that these non-GAAP financial measures provide investors with an additional tool for evaluating the Company's core performance, which management uses in its own evaluation of continuing operating performance, and a baseline for assessing the future earnings potential of the Company. The Company's non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company's industry, as other companies in the industry may calculate non-GAAP financial results differently. Non-GAAP financial results should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

Product Regulatory Advisory: This presentation is intended for the investment and financial community and not for the promotion of Apollo products or related procedures. The X-Tack is cleared for approximation of soft tissue in minimally invasive gastroenterology procedures (e.g. closure and healing of ESD/EMR sites, and closing of fistula, perforation or leaks). The Apollo IntraGastric Balloon products are approved in the US as a weight loss aid for adults suffering from obesity, with a body mass index (BMI) ≥ 30 and ≤ 40 kg/m², who have tried other weight loss programs, such as following supervised diet, exercise, and behavior modification programs, but who were unable to lose weight and keep it off. In addition, the Apollo IntraGastric balloon has received a Breakthrough Device Designation from the U.S. Food and Drug Administration for use in treating patients with a BMI between 30-40 kg/m² with noncirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis. Outside of the US the indications for Apollo IntraGastric Balloon products vary based on product version and local regulatory clearance. The Overstitch is cleared for the endoscopic placement of sutures and the approximation of soft tissue in the GI tract. The Overstitch clearance does not include procedure-specific indications for use. Although Apollo has and continues to obtain clinical data on additional uses for its products, the safety and effectiveness of these uses has not been specifically cleared or approved for commercial purposes by the U.S. Food and Drug Administration.



New Endobariatric Opportunities

STEVE BOSROCK
VP, Marketing & Medical Education



Steve Bosrock

VP, MARKETING & MEDICAL EDUCATION

Joined Apollo 2021



Building Access to Large Untapped Markets


O B E S I T Y

>\$2.9B Estimated Global Addressable Market¹



R E V I S I O N S


\$1.0B Estimated Global Addressable Market⁴



<0.2% Treated surgically²

42% of U.S. Adults are obese²


33% Increase in prevalence expected next 2 decades³



U.S. endoscopic bariatric revisions




framing our opportunity

 SEEK SURGICAL TREATMENT

>25 and Growing Endobariatric Programs at Leading Academic Centers

● **NEW** Endobariatric Programs (within last 2 years)




Driving Excitement Around Orbera®

Foundation of our franchise to address growing, global obesity crisis




- Capitalizing on macro recovery & new AGA guidelines
- Significant clinical evidence extending worldwide share leadership as competition expands category
- Increasing physician training and salesforce focus
- Initiating co-marketing programs
- Revitalizing marketing support available to dedicated EBWL practices



Amplifying Increasing Interest with Patient Marketing

U.S. ORBERA SALES

+130%



#FromTheBlog

Dietary Guide Pre & Post Orbera
Gastric Balloon Sur

and his team have helped thousands of people in North Florida achieve their weight loss goals. Our team will support you with quality care every step of the way. Schedule a Consultation today.



Non-Surgical Weight Loss Solution
Orbera® Gastric Balloon

eracare.com/

orida's Leading Orbera® Expert



TAKES UP SPACE IN THE STOMACH
SLOWS DIGESTION
PROPER PORTION CONTROL



Orbera

Home Posts Reviews Videos Photos Store



Over the next few weeks we get to dive more in depth with Keila James' success story with the Orbera Balloon. We will review topics such as why she decided on the Orbera®, picking her procedure, research, results, Dr. Snow and more. Stay tuned!

For more information on all the procedures we provide, visit

#ultimatebariatrics #lifestyle #change #weightloss #obesity #makeachange #Ultimatelife #surgery #dontkeepitasecret



ORBERA Gastric Balloon
*LIMITED TIME OFFER
Now \$7,000
~~Was \$8,500~~

Call Now: 813-499-0044
Same Day Consult / Same Day Procedure


A Division of Ideal Body Institute

What is the role for ESG?



Patients Highly Motivated in Search For Weight Loss Help

Arduous journey marred by concerns for physical health, self-image and confidence + social impacts



Of patients* are under the care of a physician for weight loss




Have met with a dietician*



Have talked with their physician about a weight loss procedure*



Patients are Interested in a Less Invasive, Effective & Durable Weight Loss Option




58%

Of patients surveyed have not considered a surgical procedure - leading concerns relate to side effects and complications of surgery*



Patients Excited About Less Invasive Treatment


Consideration expands significantly beyond those interested in traditional options



Very interested
(34%) or
interested in ESG

DRIVERS

- 46% no surgical cuts
- 44% significant weight loss
- 43% long lasting loss



Likely to see a doctor to learn more about ESG

DUE TO LEVEL OF SURGICAL INTERVENTION:

2x Greater preference for ESG over LSG

4x Greater preference for ESG over gastric bypass

“ I'm **ecstatic** after reading about it! I would love to know more and with whom I need to speak!?”

“ I like the idea of this. The **non-surgical part** is very appealing.”

Extending Application of OverStitch to Endoscopic Revisions of Bariatric Surgeries

What are Revisions?

Anatomically-driven weight regain and procedural complications can be addressed following weight loss surgery with endoscopic surgical revision.

1.4M U.S. laparoscopic sleeve & gastric bypasses 2011 to '19¹

30-50% of those will be revision candidates¹

43K U.S. revision procedures in 2019¹

>70% of top 100 U.S. Overstitch accounts perform revisions²

ENDOSCOPIC V. SURGICAL REVISION

In a peer-reviewed study³ that compared results at five years, endoscopic revision demonstrated:

- **Equivalent efficacy**
- **Improved safety profile**

| | ENDO | SURGICAL | p |
|---------------------|----------------------|--------------------------|-------|
| Efficacy at 5 years | 11.5% TBWL | 13.1% TBWL | 0.67 |
| Adverse events | 6.5% | 29.0% | 0.04 |
| Safety profile | 0 SAE rate | 19.4% SAE rate | 0.024 |

Readying for Launch* of Apollo ESG™ and Apollo Revise™

Marketing & Medical Education

- Patient market research
- Branding & messaging
- DTP co-marketing (starting with Orbera)
- Public relations
- Major conferences (DDW, ASMBS, IFSO, ACG)
- Peer to peer education programs

Reimbursement & Market Access

- Dedicated & growing R&MA team
- Patient access support
- Engaging key GI and Surgical societies
- Coding/coverage/payment strategy
- Health economics/value proposition

PRODUCT LAUNCH

Pending
510(K) Clearance

Training

- Apollo training courses
- Physician proctoring
- Virtual training resources
- Society-sponsored training (e.g., ASGE, ASMBS)

Sales Team Readiness

- Learnings from “Wave 1” accounts
- Dedicated Regional Endobariatric Manager roles
- Comprehensive account support
- Sales process and training



Readying for Launch* of Apollo ESG™ and Apollo Revise™

Marketing & Medical Education

- Patient market research
- Branding & messaging
- DTP co-marketing (starting with Orbera)
- Public relations
- Major conferences (DDW, ASMBS, IFSO, ACG)
- Peer to peer education programs

Reimbursement & Market Access

- Dedicated & growing R&MA team
- Patient access support
- Engaging key GI and Surgical societies
- Coding/coverage/payment strategy
- Health economics/value proposition

PRODUCT LAUNCH

Pending
510(K) Clearance

Training

- Apollo training courses
- Physician proctoring
- Virtual training resources
- Society-sponsored training (e.g., ASGE, ASMBS)

Sales Team Readiness

- Learnings from “Wave 1” accounts
- Dedicated Regional Endobariatric Manager roles
- Comprehensive account support
- Sales process and training

Readying for Launch* of Apollo ESG™ and Apollo Revise™

Marketing & Medical Education

- Patient market research
- Branding & messaging
- DTP co-marketing (starting with Orbera)
- Public relations
- Major conferences (DDW, ASMBS, IFSO, ACG)
- Peer to peer education programs

Reimbursement & Market Access

- Dedicated & growing R&MA team
- Patient access support
- Engaging key GI and Surgical societies
- Coding/coverage/payment strategy
- Health economics/value proposition

PRODUCT LAUNCH

Pending
510(K) Clearance

Training

- Apollo training courses
- Physician proctoring
- Virtual training resources
- Society-sponsored training (e.g., ASGE, ASMBS)

Sales Team Readiness

- Learnings from “Wave 1” accounts
- Dedicated Regional Endobariatric Manager roles
- Comprehensive account support
- Sales process and training



Readying for Launch* of Apollo ESG™ and Apollo Revise™

Marketing & Medical Education

- Patient market research
- Branding & messaging
- DTP co-marketing (starting with Orbera)
- Public relations
- Major conferences (DDW, ASMBS, IFSO, ACG)
- Peer to peer education programs

Reimbursement & Market Access

- Dedicated & growing R&MA team
- Patient access support
- Engaging key GI and Surgical societies
- Coding/coverage/payment strategy
- Health economics/value proposition

PRODUCT LAUNCH

Pending
510(K) Clearance

Training

- Apollo training courses
- Physician proctoring
- Virtual training resources
- Society-sponsored training (e.g., ASGE, ASMBS)

Sales Team Readiness

- Learnings from “Wave 1” accounts
- Dedicated Regional Endobariatric Manager roles
- Comprehensive account support
- Sales process and training



Readying for Launch* of Apollo ESG™ and Apollo Revise™

Marketing & Medical Education

- Patient market research
- Branding & messaging
- DTP co-marketing (starting with Orbera)
- Public relations
- Major conferences (DDW, ASMBS, IFSO, ACG)
- Peer to peer education programs

Reimbursement & Market Access

- Dedicated & growing R&MA team
- Patient access support
- Engaging key GI and Surgical societies
- Coding/coverage/payment strategy
- Health economics/value proposition

PRODUCT LAUNCH

Pending
510(K) Clearance

Training

- Apollo training courses
- Physician proctoring
- Virtual training resources
- Society-sponsored training (e.g., ASGE, ASMBS)

Sales Team Readiness

- Learnings from “Wave 1” accounts
- Dedicated Regional Endobariatric Manager roles
- Comprehensive account support
- Sales process and training

Outlook for Endobariatric Opportunities

energize

accelerate

lead

- Leverage and sustain growth in Orbera®
- MERIT publication
- DeNovo 510(k) clearance for Apollo ESG™ and Apollo REVISE™ (in review)
- Comprehensive launch plan
- Learn from initial EBWL practices
- Specialized sales roles

- Launch Apollo ESG™ & Apollo Revise™
- Model training programs after successful academic & private practices
- Continue cadence of supportive clinical evidence
- Support coding, coverage & payment with comprehensive reimbursement program
- Leverage society guidelines

- Establish ESG and endoscopic revisions as mainstream procedures
- Increase number of experienced practitioners
- Expand awareness of EBWL
- Increase EBWL fellowship training & education



Commercial Development - US

KIRK ELLIS

VP, U.S. Sales



Kirk Ellis

VP, U.S. SALES

Joined Apollo 2021



Early Innings of Increasing Representation

Perpetuating cycle: growth and revitalized culture attract talent

accelerating growth

Positioning organization to scale as new opportunities & focus drive faster growth

infrastructure

Leveraging more sophisticated sales processes, sales training, CRM and sales analytics to prioritize opportunities & increase effectiveness



service culture

Aligning teams around a winning, service-focused culture

expertise


Attracting industry-leading, disciplined med-tech professionals

stryker COOK® Medtronic ETHICON
OLYMPUS Ambu[†] Boston Scientific
a Johnson & Johnson company

Expanding Our U.S. Sales Capabilities


Creating strong commercial channel to support growth aspirations

- Rectifying historical underinvestment to create a foundation for growth
- Shifting from “case coverage” focus to physician support and collaboration
- Expanding team from ~30 toward ~40-45 by year end '22



Advantages of Recent Rep Hires Emerging

>65% of rep team joined under new leadership – meaningful contribution beginning



Focusing Team to Execute Growth Priorities

Piloting regional endobariatric mgr (REM) roles to facilitate comprehensive patient care



**MARKET
DEVELOPMENT
MANAGERS (MDM)**

- Provide product education, training and procedural expertise across all three product lines
- Support case coverage and help clinicians advance through the learning curve
- Identify new growth opportunities and qualify leads



**REGIONAL
ENDOBARIATRIC
MANAGERS (REM)**

- Strengthen EBWL customer relationships
- Identify & develop new EBWL accounts
- Provide best practices in supporting patients through continuum of care
- Support practice marketing (e.g., Orbera[®] co-marketing program)

U.S. Sales Outlook

energize

- Infusing team with high-caliber talent
- Creating new service culture throughout organization
- Building sales infrastructure: sales processes, sales training, CRM, sales analytics
- Piloting new Regional Endobariatric Manager roles

accelerate

- Continue to build breadth and depth of sales organization
- Adjust mix of MDMs & REMs based on market learnings

lead

- Establish a best-in-class selling organization
- Leverage for future product introductions and expansion opportunities



Commercial Development - International

MIKE GUTTERIDGE

VP, International Sales



Mike Gutteridge

VP, INTERNATIONAL SALES

Joined Apollo 2016



Well- Established O.U.S. Network

Cultivating international infrastructure to support accelerated growth

46%


FY'21 revenue from international

9

Countries with direct sales teams in Europe & Australia

49


Countries with distributor relationships



- Increasing headcount in select markets to drive OverStitch® growth
- Reigniting physician training programs
- Increased IGB adoption and market share wins
- Developing expansion plans into large, untapped markets: Japan, China, Canada

Direct O.U.S. Markets

~53% of International Revenue in FY'21




- Focused on GI adoption through HCP education
- Market share wins with Orbera365™
- Preparing for X-Tack® launch

Europe, Middle East & Africa

~28% of International Revenue in FY'21



EMEA PRODUCT MIX




- Winning market share with Orbera365™
- Entering markets with OverStitch®
- Driving OverStitch® Adoption Through Training
- Preparing for X-Tack® Launch

Asia Pacific

~5% of International Revenue in FY'21



ASIAPAC PRODUCT MIX




- Increasing regional presence
- Developing ESS & IGB markets
- Increasing market awareness
- Market development in China and Japan

Latin America

~15% of International Revenue in FY'21



LATAM PRODUCT MIX



- Developing OverStitch market
- Developing Core GI market
- Preparing for X-Tack® Launch



O.U.S. Sales Outlook



energize

- Increasing headcount in select markets to drive OverStitch[®] growth
- Reigniting physician training programs
- Increasing IGB adoption & share wins
- Preparing for X-Tack[®] launch
- Developing expansion plans in large, untapped markets: Japan, China, Canada

accelerate

- Establish X-Tack[®] as a new standard in GI defect closure
- Leverage MERIT trial publication to support reimbursement efforts in key countries
- Continue to drive clinical data collection supporting utilization of OverStitch[®], Orbera[®], and X-Tack[®]

lead

- Well-established infrastructure scales to support broad O.U.S. presence
- Work with physician societies to train next generation of doctors



Clinical Strategies

TIFFANIE GILBRETH

VP, Clinical and Medical Affairs



Tiffanie Gilbreth

VP, CLINICAL & MEDICAL AFFAIRS

Joined Apollo 2012

stryker®



COVIDIEN

Changing Practice with Clinical Validation

Massive inflection at DDW strengthens significant clinical library

significant clinical library




DDW Presentations/Posters/Cases

~1160
Publications

622¹ **OverStitch®- Related (all applications)**
256 ESG specific; 130 TORe/ Revision specific

525² **Orbera® / BIB-Related**
94 NAFLD/ NASH specific

13³ **X-Tack® - Related**



OverStitch[®] for Defect Closure / Fixation

previous

new developments @ DDW

~270

Peer-reviewed clinical publications¹

Prospective study of utility of OverStitch Sx endoscopic suturing system to close large defects after endoscopic submucosal dissection (Othman)

>50

Different clinical applications¹

Endoscopic management of very-delayed-onset tracheoesophageal fistula and esophagocutaneous fistula after neonatal colonic interposition for esophageal atresia (Lin)

Limitless! treatment of giant gastric lesion(41cm) with endoscopic submucosal dissection (Aslan)

Endoscopic ultrasound-directed transgastric ercp (edge): a multicenter US study on long term follow-up and fistula closure (Shah-Khan)



X-Tack[®] for Defect Closure / Fixation

previous

new developments @ DDW

13

Peer-reviewed clinical publications¹

Efficacy, feasibility and safety of the X-Tack endoscopic helix tacking system: a multicenter experience (Sharaiha)

>20

Different clinical applications¹

“Holey moly”: comprehensive management of an eroded aortic prosthetic graft (Hu)

Complicated gastro-cutaneous fistula closure with x-tack endoscopic helix tacking system (Sultan)

Novel through-the-scope suture closure of colonic EMR defects (Bi)

Through-the-scope suture closure of non-ampullary duodenal EMR defects (Almario)



US multi-society task force (AGA, ACG, ASGE) recommends prophylactic closure for lesions >20mm, right colon²



X-Tack[®] - DDW Clinical Highlights

THROUGH-THE-SCOPE SUTURE CLOSURE OF NON-AMPULLARY DUODENAL EMR DEFECTS (Almario)

7 centers 35 patients 71% achieved complete closure¹

- Large post EMR defect (36 ± 23mm)
- High rate of antithrombotic use (22.9%)
- Complete closure achieved (71.4%)
- Only 1 TTSS system used on average (range 1-3)
- 1 Intraprocedural bleeding event (managed endoscopically)

“ TTSS is an effective tool for closure of mucosal defects after EMR of large non-ampullary duodenal defects.

NOVEL THROUGH-THE-SCOPE SUTURE CLOSURE OF COLONIC EMR DEFECTS (Bi)

13 centers 100 patients 73% achieved complete closure¹

- Over 50% of the defects were >40mm
- Complete closure achieved (73%)
- 1 TTSS system used on average (range 1-2)
- Delayed bleeding occurred in 1 case (managed endoscopically using 2 XTack systems)

“ TTSS was effective in achieving complete closure of large post-EMR defect sites, despite large lesion size.

previous

new developments @ DDW

~525 Peer-reviewed clinical publications¹

Intragastric balloon outcomes on diabetes, hypertension and dyslipidemia at 6 months: a systematic review and meta-analysis (Shah)

>32K Patients included in studies²

Intragastric balloon placement prior to bariatric surgery does not lead to an increased risk of adverse events following surgery (Platt)

✓ AGA guidelines have spurred increasing interest in IGB use⁴



Suturing for ESG

previous

new developments @ DDW

>250 Peer-reviewed clinical publications¹

Endoscopic sleeve gastropasty in class III obesity: weight loss and metabolic outcomes in 339 consecutive patients (McGowan)

>6,500 Patients included in studies¹

Metabolic and anthropometric changes after endoscopic sleeve gastropasty (Sarkar)


>5 year Follow-up data available²

Endoscopic sleeve gastropasty significantly reduces the comorbidities of the metabolic syndrome at 5-year follow-up (Westerveld)


Direct comparative efficacy and safety of endoscopic sleeve gastropasty vs. Laparoscopic sleeve gastrectomy: a systematic review and meta-analysis (Beran)



ESG Can Meet Unmet Clinical Needs



MERIT Results: Efficacy & Durability



- **49.2% ± 32**, target 25%
- **Delta vs LS 45% [95% CI 39 – 51]**, target 15%
- **77%** responder rate ≥ 25% EWL
- **%TBWL 16.3 ± 7%** among responders

MERIT Results: Significant Impact on Comorbidities

ESG compared to standard of care

| | ESG | | SoC | | p |
|---|---------|--------|---------|--------|--------|
| | Improve | Worsen | Improve | Worsen | |
| Diabetes Mellitus Type II (DMII) | 93% | 0% | 15% | 44% | <0.001 |
| Metabolic Syndrome + NAFLD + Inflammation | 83% | 0% | 35% | 38% | <0.001 |
| Hypertension (HTN) | 67% | 6% | 40% | 23% | =0.01 |


diabetes mellitus type II (DMII)

| ESG | Improve | Worsen | p |
|--------------------|---------------------|---------------------|---------|
| HOMA-IR | -3 (SD 6.354) | +1.35 (SD 3.2) | P=0.01 |
| HgA1c (Diabetics) | -0.87 (SD 1.1) | +0.39 (SD 0.7) | P<0.001 |
| HgA1c (baseline>7) | -1.77 (SD 0.755) | +0.16 (SD 0.635) | p<0.001 |

metabolic syndrome + nafld + inflammation

| ESG | Improve | Worsen | p |
|--------------------------------|----------------------|----------------------|--------|
| Hepatic Steatosis Index (HSII) | -2.24 (SD 3.075) | -0.61 (SD 3.409) | P=0.01 |
| CRP | -1.78 (SD 4.04) | +0.51 (SD 3.525) | P<0.01 |
| Waist/ Hip Ratio (% Change) | -2.91 (SD 8.5188) | -0.36 (SD 7.2852) | P=0.02 |

MERIT Results: GERD Improved



Suturing for Revision of Previous Bariatric Procedures

previous

new developments @ DDW

>130 Peer-reviewed clinical publications¹

>3000 Patients included in studies¹

>7 year Follow-up data available²

Transoral gastric outlet reduction for post-prandial hypoglycemia after roux-en-y gastric bypass (Dunn)

Medium term efficacy of the endoscopic transoral outlet reduction for weight regain and dumping syndrome after gastric bypass (Pentecorvi)

Factors associated with weight loss after endoscopic transoral outlet reduction (TORE); (Meyers)

GLP-1 analogues in combination with revisional endoscopic sleeve gastroplasty: 24-month follow-up (Hoff)

Combination therapy yields improved safety and similar efficacy compared to surgical revision for the management of weight regain following roux-en-y gastric bypass (Jirapinyo)





Closing

Our Priorities

Initiatives to accelerate growth across products & geographies



Expand Core GI Defect Closure & Fixation

continuing to drive OverStitch adoption & X-Tack™ penetration; OUS expansion

Leverage Orbera® Resurgence

creating sustainable growth in endobariatric practices


Prepare for Apollo ESG™ & Apollo Revise™

laying groundwork for successful commercial releases

Advance the Organization

investing to create a world-class foundation for growth

Growth Outlook



energize

Invest to build a foundation for growth

accelerate

Leverage new clinical indications and applications

lead

Become the standard of care